AstraZeneca’s Three Phase III Lung-Cancer Trials: What the Results Mean

AstraZeneca’s three Phase III non-small-cell lung cancer updates delivered a clear strategic message: targeted treatments performed well in genetically defined patient groups, while the company’s attempt to challenge pembrolizumab-based therapy with the investigational bispecific volrustomig failed in a broader first-line setting.

The result was net-positive for AstraZeneca’s lung-cancer franchise but mixed for its pipeline. The market’s restrained response—AZN rose about 1.6% intraday to roughly 11,650 pence—suggested that investors valued the two wins without treating them as a full reset of the company’s development risks.

The three trials at a glance

Trial	Treatment and setting	Result	Strategic significance
SAFFRON	Tagrisso plus Orpathys after Tagrisso progression in MET-driven EGFR-mutated NSCLC	Positive for progression-free survival (PFS) and overall survival (OS)	Extends Tagrisso’s role into a resistance setting
DESTINY-Lung04	Enhertu as first-line treatment for HER2-mutant advanced NSCLC	Positive for PFS; OS follow-up continues	Establishes a potential targeted alternative to chemo-immunotherapy
eVOLVE-Lung02	Volrustomig plus chemotherapy as first-line treatment for metastatic NSCLC with low PD-L1 expression	Discontinued for futility	Weakens the near-term lung-cancer case for volrustomig

SAFFRON: a survival win after Tagrisso progression

SAFFRON tested Orpathys, also known as savolitinib, in combination with Tagrisso, or osimertinib. The study enrolled patients with EGFR-mutated, locally advanced or metastatic NSCLC whose disease had progressed on Tagrisso and whose tumors showed MET overexpression or amplification. The combination produced statistically significant and clinically meaningful improvements in both PFS and OS compared with platinum-based doublet chemotherapy.

AstraZeneca described SAFFRON as the first global Phase III trial to show significant benefits in both endpoints in this post-Tagrisso, MET-driven setting. That matters clinically because the trial addresses a defined mechanism of resistance rather than abandoning targeted therapy immediately after progression.

The result also supports AstraZeneca’s effort to position Tagrisso as a continuing treatment backbone across stages and resistance settings. The commercial opportunity is nevertheless focused: SAFFRON does not apply to every patient with EGFR-mutated NSCLC, only to those who meet the trial’s post-Tagrisso and MET-related criteria.

DESTINY-Lung04: Enhertu moves into first-line HER2-mutant disease

DESTINY-Lung04 evaluated Enhertu, or trastuzumab deruxtecan, as first-line treatment for patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC. The comparator was platinum-pemetrexed chemotherapy plus pembrolizumab, described as the global standard of care in the trial. Enhertu achieved a statistically significant and clinically meaningful improvement in PFS.

The companies said this was the first Phase III result in this setting to show a PFS benefit for a HER2-directed medicine over the global standard of care. If supported by the full dataset and regulatory review, the finding could change first-line treatment discussions for this molecularly defined group.

The announcement was a topline result, however. The study was continuing to assess secondary endpoints, including OS, and the detailed efficacy and safety data had not yet been fully reported in the cited announcement. That means the result is important, but its ultimate clinical and commercial impact depends on the size and durability of the benefit, the complete safety profile, and regulatory decisions.

The population is also defined by HER2 mutations, making it narrower than the broad metastatic NSCLC market. Its importance therefore lies less in immediate volume than in demonstrating that Enhertu can compete directly with first-line chemo-immunotherapy in a precision-oncology setting.

eVOLVE-Lung02: volrustomig fails to displace pembrolizumab plus chemotherapy

AstraZeneca discontinued eVOLVE-Lung02 after an Independent Data Monitoring Committee concluded that volrustomig plus chemotherapy was unlikely to meet either of the trial’s dual primary endpoints: PFS or OS. The Phase III study compared the regimen with pembrolizumab plus chemotherapy in first-line metastatic NSCLC with PD-L1 expression below 50%.

The decision followed a planned review of the data and was based on futility, rather than a disclosed new safety signal. AstraZeneca said the safety profile was consistent with the known profiles of the individual medicines.

This was a significant pipeline setback because the trial tested volrustomig against an established chemo-immunotherapy benchmark in a substantially broader treatment setting than the biomarker-selected populations in SAFFRON and DESTINY-Lung04. The failure does not invalidate the two targeted results, but it shows that success in a molecularly selected subgroup does not automatically translate into success against standard immunotherapy in a wider first-line population.

Why the patient populations matter

The three trials were not testing the same commercial or clinical opportunity:

• SAFFRON focused on patients whose EGFR-mutated cancer had progressed on Tagrisso and whose tumors had MET overexpression or amplification. Its value is the ability to treat a specific resistance pathway with an all-oral targeted combination.
• DESTINY-Lung04 focused on previously untreated advanced NSCLC with HER2 mutations. Its potential is a new first-line targeted option for a genetically defined subgroup.
• eVOLVE-Lung02 addressed first-line metastatic NSCLC with lower PD-L1 expression, comparing an experimental immunotherapy combination with pembrolizumab plus chemotherapy.

This distinction helps explain the apparently contradictory news. The two positive trials can strengthen AstraZeneca’s position in precision oncology without generating the same immediate patient-volume opportunity as a successful all-comer or broadly defined first-line trial. Conversely, the volrustomig failure affects a wider strategic ambition: replacing or improving on a deeply established chemo-immunotherapy approach.

What the announcements signaled

AstraZeneca and HUTCHMED emphasized that SAFFRON showed both PFS and OS benefits and reinforced Tagrisso’s role as a backbone therapy in EGFR-mutated lung cancer. AstraZeneca and Daiichi Sankyo highlighted Enhertu’s first-in-setting PFS result against chemo-immunotherapy and said the data would be presented at a future medical meeting and shared with regulators.

For eVOLVE-Lung02, the key message was more limited: an independent committee judged that the trial was unlikely to succeed on either primary endpoint, so AstraZeneca stopped it. The company’s statement also indicated that no new safety signal had prompted the decision.

Taken together, the announcements portray a company with meaningful strength in biomarker-driven lung cancer, but with uneven performance when it moves into broader immuno-oncology competition.

How investors reacted

The immediate share-price response was modestly positive. AstraZeneca stock was reported up 1.6% intraday at around 11,650 pence after the three updates. Other market snapshots showed a smaller gain and a year-to-date decline of roughly 16%, indicating that the precise move depended on the timing of the quote and that the broader backdrop remained weak.

The reaction suggests a partial offset rather than a major re-rating. SAFFRON offered the clearest survival signal, while DESTINY-Lung04 added support for the Enhertu partnership and AstraZeneca’s precision-oncology strategy. The eVOLVE-Lung02 discontinuation, however, removed a late-stage opportunity in a broader first-line market.

The trial news also arrived amid wider uncertainty around AstraZeneca. Reuters reported that shares had fallen about 9% on August 3 after reports of possible merger discussions with Bristol Myers Squibb, the company’s largest decline since 2020. That context makes it difficult to attribute the stock’s broader performance to the lung-cancer trials alone.

Bottom line

SAFFRON was the most important result for AstraZeneca’s existing lung-cancer franchise: it showed that Tagrisso plus Orpathys improved both PFS and OS in a biomarker-selected, post-Tagrisso population with MET-driven resistance. DESTINY-Lung04 strengthened the case for Enhertu as a first-line treatment in HER2-mutant advanced NSCLC by improving PFS against chemo-immunotherapy, although fuller data and regulatory review remain important.

The eVOLVE-Lung02 failure was a reminder that a strong precision-oncology portfolio does not guarantee success in the broader, highly competitive first-line immunotherapy market. For investors, the package was encouraging enough to cushion the setback—but not strong enough to eliminate concerns about pipeline execution, commercial reach, and AstraZeneca’s wider strategic uncertainty.